Alder won’t solve Lundbeck’s headaches
Lundbeck needed a deal, but it could struggle against strong competition in migraine.
Sakura blossoms for Roche, setting up Soliris battle
A phase III win for Roche’s satralizumab has added to Alexion’s Soliris woes.
Should the diabetes development road end for Sanofi?
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…
Glaxo dips a lonely big pharma toe into the coeliac space
With the buyout of Sitari Pharmaceuticals, Glaxosmithkline becomes only the second major drug maker to have an interest in coeliac disease.
Abbott’s Tendyne valve shows early promise in calcification
Feasibility trial success could mean a new therapy, but not for a few years yet.
Sumitomo bets on Roivant to solve its patent expiry woes
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Stryker spends $500m to re-up on robots
Deal is the fifth largest robotics surgery purchase ever, and the second big move from Stryker.
Ardelyx Amplified by first hyperphosphataemia success
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
Vertex spends nearly $1bn on Semma's unproven diabetes cell tech
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.